Back to top
more

Abbott Laboratories (ABT)

(Delayed Data from NYSE)

$119.39 USD

119.39
6,741,790

+1.50 (1.27%)

Updated Oct 18, 2024 04:00 PM ET

After-Market: $119.40 +0.01 (0.01%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value D Growth A Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 28% (71 out of 250)

Industry: Medical - Products

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Integra LifeSciences (IART) Q1 Earnings Beat, Margins Rise

by Zacks Equity Research

Integra LifeSciences' (IART) quarterly performance is majorly hurt by the company's exit from the transition services agreements covering Western Europe.

Illumina (ILMN) Q1 Earnings Beat Estimates, Gross Margin Up

by Zacks Equity Research

Illumina's (ILMN) NextSeq and MiSeq placements witness year-over-year growth, with the strength of the former being driven by solid demand for TSO500.

GNC Holdings (GNC) Reports Q1 Earnings, Revenues Down Y/Y

by Zacks Equity Research

Despite year-over-year decline in earnings and revenues, better performing International segment and key developments favor GNC Holdings (GNC) in Q1.

PerkinElmer (PKI) Beats on Q1 Earnings, Hikes '19 Guidance

by Zacks Equity Research

PerkinElmer's (PKI) Q1 earnings gain from top-line growth, solid show by Diagnostics segment and strong margins. However, negative currency movement remains a headwind.

Omnicell (OMCL) Earnings and Revenues Beat Estimates in Q1

by Zacks Equity Research

Omnicell (OMCL) gains from solid segmental contributions in Q1; margins expand.

Cerner (CERN) Earnings and Revenues Meet Estimates in Q1

by Zacks Equity Research

Cerner (CERN) gains from Professional Services unit in first-quarter 2019. A decline in bookings raises concern.

Zacks.com featured highlights include: PepsiCo, Raymond James, Kansas City Southern, Fortive and Abbott Laboratories

by Zacks Equity Research

Zacks.com featured highlights include: PepsiCo, Raymond James, Kansas City Southern, Fortive and Abbott Laboratories

Varian (VAR) Q2 Earnings Lag Estimates, Gross Orders Surge

by Zacks Equity Research

Varian (VAR) gains from solid segmental contributions in Q2, raises revenue guidance.

Align Technology (ALGN) Beats on Q1 Earnings, Margins Down

by Zacks Equity Research

Align Technology (ALGN) reports promising top-line numbers on double-digit increase in Invisalign case shipments from a year ago.

Swayta Shah headshot

Solid Sales Growth Makes These 5 Stocks Worth Buying Now

by Swayta Shah

Sales growth is an early indicator of the company's future earnings performance.

Is Abbott Laboratories (ABT) Stock Outpacing Its Medical Peers This Year?

by Zacks Equity Research

Is (ABT) Outperforming Other Medical Stocks This Year?

Abbott (ABT) Q1 Earnings Beat Estimates, Organic Sales Solid

by Zacks Equity Research

Abbott (ABT) reports strong and consistent EPD and Medical Devices performance organically in Q1.

Abbott (ABT) Surpasses Q1 Earnings and Revenue Estimates

by Zacks Equity Research

Abbott (ABT) delivered earnings and revenue surprises of 3.28% and 0.91%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?

Tracey Ryniec headshot

5 Spectacular Large Cap Earnings Charts

by Tracey Ryniec

Which large cap earnings reports should you be watching this week?

Can Medical Devices Strength Drive Abbott (ABT) Q1 Earnings?

by Zacks Equity Research

Abbott (ABT) expects high single-digit growth in Medical Devices' sales in first-quarter 2019 and continued double-digit growth in certain sub-segments.

Will Abbott's (ABT) Steady Overall Growth Aid Q1 Earnings?

by Zacks Equity Research

At the end of 2018, Abbott (ABT) posts some encouraging data, buoying investors' optimism on its Diabetes Care segment.

Abbott (ABT) Earnings Expected to Grow: Should You Buy?

by Zacks Equity Research

Abbott (ABT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Abbott (ABT) Gains As Market Dips: What You Should Know

by Zacks Equity Research

Abbott (ABT) closed at $78.67 in the latest trading session, marking a +0.19% move from the prior day.

Abbott (ABT) Stock Sinks As Market Gains: What You Should Know

by Zacks Equity Research

In the latest trading session, Abbott (ABT) closed at $79.50, marking a -0.15% move from the previous day.

Nevro (NVRO) Plagued by Issues in Australia & Stiff Rivalry

by Zacks Equity Research

Nevro's (NVRO) international sales get affected by weakness in Australia.

Abbott (ABT) Gains As Market Dips: What You Should Know

by Zacks Equity Research

Abbott (ABT) closed at $78.23 in the latest trading session, marking a +0.33% move from the prior day.

Thermo Fisher to Buy Brammer Bio, Tightens Gene Therapy Grip

by Zacks Equity Research

On closure of the acquisition deal, Brammer Bio will be integral to Thermo Fisher's (TMO) pharma services business within its Laboratory Products and Services wing.

Abbott's New CE Mark to Boost Core Laboratory Diagnostics Arm

by Zacks Equity Research

Abbott's (ABT) Alinity m diagnostics system and assays will provide increased flexibility and time efficiency while catering to the rising demand for infectious disease testing.

Quest Diagnostics Grows on New Pacts Amid Reimbursement Issue

by Zacks Equity Research

Quest Diagnostics' (DGX) partnership with UnitedHealthcare to operate as a preferred national laboratory seems strategic for the latter's customers.

Sweta Killa headshot

6 Excellent Dividend Growth Stocks to Buy Now

by Sweta Killa

The return of volatility with the escalation of global growth concerns and the risk of recession in the United States raises the appeal for dividend growth stocks.